Related Experiment Video

Updated: Jul 16, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Rational combinations of siRNAs targeting Plk1 with breast cancer drugs

B Spänkuch1, E Kurunci-Csacsko, M Kaufmann

  • 1Department of Obstetrics and Gynecology, Medical School, JW Goethe-University, Frankfurt, Germany. birgit.spaenkuch@t-online.de

Oncogene
|March 21, 2007
PubMed

Insights

Combining polo-like kinase 1 (Plk1)-specific small interfering RNAs (siRNAs) with paclitaxel or Herceptin synergistically enhances breast cancer cell sensitivity. This approach utilizes low drug concentrations, potentially reducing side effects and overcoming resistance for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Standard breast cancer therapies like paclitaxel and Herceptin can cause severe side effects and drug resistance.
  • Polo-like kinase 1 (Plk1) is a key regulator of mitosis, and its inhibition can induce mitotic catastrophe in cancer cells.

Purpose of the Study:

  • To investigate the synergistic effects of Plk1-specific small interfering RNAs (siRNAs) combined with paclitaxel or Herceptin on breast cancer cell sensitivity.
  • To determine if this combination therapy can enhance drug efficacy and reduce required drug concentrations.

Main Methods:

  • Breast cancer cell lines (MCF-7, SK-BR-3, MDA-MB-435, BT-474) and primary human mammary epithelial cells were transfected with Plk1-specific siRNAs.
  • Cells were subsequently treated with paclitaxel or Herceptin.
  • Cell proliferation, apoptosis, cell cycle distribution, and caspase pathway activation were analyzed.

Main Results:

  • Downregulation of Plk1 using siRNAs increased the percentage of cells in the G(2)/M phase.
  • Combined treatment with Plk1 siRNAs and paclitaxel significantly increased apoptosis in all tested breast cancer cell lines.
  • Synergistic enhancement of sensitivity to paclitaxel and Herceptin was observed, with significant antiproliferative effects at low drug concentrations.

Conclusions:

  • The combination of Plk1-specific siRNAs with paclitaxel or Herceptin demonstrates synergistic efficacy in breast cancer treatment.
  • This combination strategy holds promise for improving drug sensitivity and potentially reducing toxicity in clinical settings.
  • Further preclinical trials are warranted to evaluate this rational combination therapy.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...